Phase 4 Asthma Trial, Recruiting NCT06705764 Sponsor: University of Alberta Condition: Asthma
Back to Asthma

Phase 4 Asthma Trial, Recruiting

NCT06705764
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are willing and able to give their informed consent before any study procedures begin
  • People aged 18 to 55 years (male or female)
  • People who have been diagnosed with asthma by a doctor
  • People who have been prescribed a high-dose inhaled corticosteroid (a strong preventer inhaler) plus at least one other asthma controller medication for at least 3 months before joining the trial
  • People who have had at least one moderate or severe asthma flare-up in the past 12 months
  • Women of childbearing age who have a negative pregnancy test at the start of the trial
  • Women who are at least 1 year past menopause, have had a surgical procedure that prevents pregnancy, or are using an approved combination of contraception methods for the duration of the study and for 3 months after the last dose of study medication (a barrier method with spermicide is required; oral contraception alone is not sufficient, but can be used alongside a barrier method with spermicide)
  • Blood donors who are willing not to donate blood during the study and for 3 months after the last dose of study medication
  • People who are willing and able to follow all study procedures

Who may not be able to join:

  • People who are involved in planning or running this study
  • People who have previously been enrolled in this same trial
  • People who have taken part in another clinical trial involving an experimental treatment in the last 6 months
  • People with a known allergy or sensitivity to Tezepelumab or any of its ingredients
  • People who are hospitalised at the time of their screening appointment
  • People who test positive for Hepatitis B or Hepatitis C at screening
  • People who are known to be HIV positive
  • Current smokers with a smoking history of more than 10 pack-years, ex-smokers with a smoking history of more than 10 pack-years, or people who use e-cigarettes (current smokers with a history of fewer than 10 pack-years may be permitted)
  • People with a known history of drug or alcohol misuse within the past year
  • People taking certain medications known to affect heart rhythm in specific ways (confirm with trial site)
  • People who have previously had to stop a medication due to its effect on heart rhythm (a condition called QT prolongation)
  • People born with a heart condition called congenital long QT syndrome
  • People whose kidneys are not functioning well enough, based on a specific calculation (confirm with trial site)
  • Women who are currently pregnant or breastfeeding
  • People with certain types of heart rhythm problems that cause symptoms or require treatment; however, people with atrial fibrillation that is well controlled with medication may be permitted (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Irvin Mayers, MD, University of Alberta

Phone: 7804923741

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Registry
ClinicalTrials.gov
Start date
11 May 2026
Est. completion
1 November 2026

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Proportion of patients who have moderate and severe exacerbations of asthma

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov